Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Squamous Cell Carcinoma of the Gallbladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced May 21, 2026, 11:20 PM EDT
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced May 21, 2026, 11:20 PM EDT
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions
capecitabine, gemcitabine hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced May 21, 2026, 11:20 PM EDT
Conditions
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Undifferentiated Gallbladder Carcinoma, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Interventions
Erlotinib Hydrochloride, Sorafenib Tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
141
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced May 21, 2026, 11:20 PM EDT
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced May 21, 2026, 11:20 PM EDT